对于其结合belrestotug和detaurlimab的肺癌第二阶段研究,iTeos Therapeutics报告了比单独使用detaurlimab的反应率更高. iTeos Therapeutics reports a higher response rate for its Phase 2 lung cancer study combining belrestotug and dostarlimab compared to dostarlimab alone.

据 iTeos Therapeutics 报告,其第 2 期 GALAXIES Lung-201 后续研究数据显示, belrestotug 和 dostarlimab 的组合在未经治疗的,PD- L1 高发型非小细胞肺癌 (NSCLC) 患者中具有前景. iTeos Therapeutics reported promising follow-up data from its Phase 2 GALAXIES Lung-201 study, evaluating the combination of belrestotug and dostarlimab in untreated patients with advanced PD-L1 high non-small cell lung cancer (NSCLC). 研究显示,客观答复率(ORR)为63.3%至76.7%,经确认的ORR约为60%,远远高于仅Dostarlimab。 The study revealed an objective response rate (ORR) of 63.3-76.7%, with a confirmed ORR of about 60%, significantly higher than dostarlimab alone. iTeos将在2024年9月16日的电话会议上讨论这些调查结果。 iTeos will discuss these findings in a conference call on September 16, 2024.